List of Generics Companies in India - 28

Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.

Biodeal Pharma is a WHO-GMP Certified and PIC/S approved pharmaceutical manufacturing Company and is a highly respected name as a fully integrated Indian Manufacturing Company located amidst the green fields of Himachal Pradesh and are leading global providers in Pharmaceuticals, Cosmetics and Nutraceuticals. Owing to persistent values of customer satisfaction, unsurpassed quality standards, human safety, innovation and serves a clientele of more than 30 reputed companies like TORRENT, DRL, SUN PHARMA, DR. MOREPEN, CADILA, ZYDUS, ALEMBIC, ALKEM, WOCKHARDT, INTAS, ZUVENTUS, IPCA, INDOCO, MACLEODS , KOYE PHARMA, ERIS LIFESCIENCES , AJANTA PHARMA, etc. BIODEAL offers Products on Third Party Basis for Export as well as Domestic business on contract manufacturing basis. Our Sections:- • Tablets (Drugs & Nutraceuticals) • Capsules (Drugs & Nutraceuticals) • Dry Powder Inhaler Capsules • Oral Spray (Food) • Dry Sachet • Dusting Powder • Nasal Sprays • Lotion • Ointment • Cosmetics Biodeal has a strong presence in NUTRACEUTICALS with VITAGEN, offering Vitamins, Multi complex, Antioxidants, Amino acids, Omegas, Herbals and varied categories to meet specific needs. Besides most common tablet or capsule formats, VITAGEN offers the biggest range of innovative delivery forms which are easy to consume and have a great taste, e.g., Spray, Chewable, Sachets. The large number of bioavailable and well absorbed products provides the opportunity for everyone to be able to get a Nutrition therapy according to individual needs. Also introducing all new range of VITAGEN Sunscreens, specifically developed formulations for sun protection and skin care. Vegetarian prebiotic capsule is used in all the products, which are generally better consumed by digestive system, and ideal for those who do not want to take animal gelatin for moral, diet or religious reason, as well as opting for a healthier alternative.

Biophore is a research driven global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) having its operations based in Hyderabad, India and also has a registered office in New Jersey, USA. Biophore has two dedicated R&D facilities in Hyderabad and Vishakapatnam. The research facilities are fully equipped with wide range of R&D and process equipment from USA with reaction capabilities from milligram to kilogram. Ever since its establishment in 2007, Biophore recognized that there were two ways of growing the API business: manufacture a large API product basket, or pick a handful of promising APIs in select therapeutic categories and grow them over the long-term. Biophore consciously chose the latter option and focused on not only building competencies and adding scale in those segments but more importantly, building efficiencies that would make it an undisputed leader in these products of choice. The product range is constantly expanded through its own R&D, process development, technology transfers, joint ventures and collaborations. Biophore's core strength lies in development of non – infringing routes for comprehensive range of bulk actives and intermediates, development of niche APIs, oncology APIs, APIs for MRI contrast agents and APIs for NCE - 1 filing. Biophore has made strategic investments in two manufacturing facilities. Sionc pharmaceuticals & Azico – Biophore, Both located at Vishakapatnam. Among them Sionc, a multi-purpose plant has passed FDA inspection in 2013 & 2016 with no observations on the Form 483. This is the reason to be proud and confirmation of the highest quality standards of Biophore. Our other facility Azico – Biophore is also a n FDA approved facility that strictly complies with cGMP procedures and maintains well documented SOPs, with a modern quality control laboratory thereby ensuring the production of highest quality APIs.

Century Pharmaceuticals Ltd is a privately held Pharmaceutical Company based out Vadodara, India. For more than 30 years, we have emerged as a respectable name in the industry. Our services include manufacturing APIs, facilities for contract manufacturing, Biotechnology research, API research, stability studies, and more.

"We are a company based in India, responsibly offering pharmaceutical products across the globe!" We are a public listed company. We are associated with many companies worldwide. We export from India various API & intermediates, pharmaceutical products, critical care injections, plasma, blood, biological products across the globe. We import vaccines in India from the top most manufacturers of the world. We have our own marketing team in India. Our team promotes our brand pharmaceutical formulations, especially injectables We have an excellent sourcing & qualified supply & regulatory team.

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing. The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

A Public limited firm in the business of manufacturing and supply of High quality Generic Active Pharmaceutical Ingredients (APIs) to the Global Pharmaceutical Industry since 1995.

Geno has the W .H.O. - G.M.P. approved facilities at Mapusa, Goa to manufacture Tablets, Capsules, Syrups and Ointments in the Plant extending over 5 acres of area. Geno is now an ISO 9001:2008 certified company with revised schedule M compliance.

Established in Hyderabad, India in 1978, Gland Pharma is one of the fastest-growing small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. Gland Pharma has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities. We are focused on meeting diverse injectables needs with a stable supply of affordable and high-quality products. We have established a portfolio of injectables products across various therapeutic segments and delivery systems and are present in sterile injectables, oncology and ophthalmics with a focus on complex injectables.

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark's culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark's core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation' (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry. Equipped with a world-class infrastructure manned by best-in-class personnel & driven by the core values of knowledge, innovation and excellence, within a relatively short period, Laurus labs emerged as a segment-leading manufacturer of high quality APIs, a preferred partner for NCE development & manufacture & a trusted source of specialty ingredients for the nutraceutical industry. Given the strengths, capabilities & experience, Laurus Labs is uniquely positioned to help its clients in their endeavor of ‘quicker to market' & thus contributing towards improving access to quality & affordable healthcare worldwide.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

M.J. Biopharm is a fully integrated biopharmaceutical company offering human insulin, analogue insulin, GLP1 agents, both as drug substance and formulations. M.J. offers partnering opportunities in development and commercialisation of generic products. Our process development expertise is from proof of concept to commercial scale and yield optimisation. We also offer contract manufacturing in vials, ampoules, cartridges and disposable pens. Contact email address: linkedin@mjbiopharm.com

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 22 state-of-the-art manufacturing facilities (15 API and 7 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly. Backed by a dedicated and experienced team of over 14,000 qualified professionals, the organization has earned a global distinction for its innovation, quality and speed of delivery besides achieving the following: > About 900+ national and international patent applications filed > Product portfolio of 450 + APIs & 300+ Finished Dosages > Over 35 major therapeutic offerings covering Oncology, Cardiology, CNS, Diabetes, Nephrology, Urology, Gastroenterology, Orthopaedics etc. > World No. 1 in active US DMF Filings > Won the trust of more than 40 Million patients across 100+ countries The organizational environment at MSN Labs integrates multiple disciplines and functions by effective implementation of goals and objectives through technology coupled with Integrity, Imagination and Innovation. The company's proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight-driven IT, and world-class facilities remain at the heart of its continuing success. We own a track record of growing at an exponential pace since our inception. From 22 Million USD in 2005 to achieving about 670 Million USD turnover in FY 2021-22 and counting, we continue to expand our growth and global footprint by creating innovative solutions for tomorrow's healthcare requirements.

NATCO Pharma is a vertically integrated company dedicated to the development, manufacture, and supply of pharmaceutical and agrochemical products. Established with the mission to make specialty medicines accessible to all, we are rooted in integrity, respect, openness, collaboration, creativity, and quality. Founded in 1981, we now have a strong global presence in over 50 countries. NATCO has emerged as an esteemed pharmaceutical company with a presence in Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) in both domestic and international markets. NATCO Pharma's focused approach has led to expanded capabilities across diverse therapy segments, particularly in oncology. We operate in two key segments: Pharmaceuticals and Agrochemicals. Our expertise excels in the FDF division, crafting intricate pharmaceutical solutions tailored to specific therapeutic needs. In the manufacturing of APIs, we maintain high quality and adhere to all regulatory standards with a focus on innovation. In the Crop Health Sciences (CHS) division, we produce high-value agricultural input products to meet farmers' demands, including environmentally safer biocontrol products. Operating globally, NATCO's work contributes to its diverse market presence. NATCO believes in sustainable and balanced growth through the synergy of our talented workforce and an innovative culture. We are dedicated to maximizing shareholder value creation through innovation, employee engagement, process and system optimization.

Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end chemistry-related solutions provider for the pharmaceutical industry. With three FDA-inspected facilities, 846+ DMFs, 1000+ employees and customers in more than 85 countries, Neuland supports some of the world's best-known and most successful pharmaceutical research and manufacturing companies. The spirit of research and professionalism pervades Neuland's corporate culture. Neuland's manufacturing capabilities and competence in complex chemistry provides reliable and superior quality products and services. Neuland is a leading manufacturer of APIs and provides customers with: * Contract research, contract manufacturing and generic APIs * 75 API's in 10 diverse therapeutic areas * 3 regulatory approved manufacturing facilities * 40,000 sq. ft. state-of-the-art R&D facility in Hyderabad * 300 + scientists working in R & D * Listed on the Bombay Stock Exchange and National Stock Exchange * Worldwide compliant facilities (WHO, US FDA, EMA, PMDA, TGA, KFDA, ANVISA, ISO 14001, ISO 27001 and OHSAS 18001 Certified) Neuland's core strategy is to never to compete with its customers. Neuland focuses purely on serving the global pharmaceutical firms with API manufacturing, and contract research & manufacturing services.

Orbicular Pharmaceutical Technologies Pvt. Ltd. is a Specialty Pharmaceutical Company that develops niche and complex pharmaceutical dosage forms for licensing to global partners. We are based out of Hyderabad, India and have a state-of-the-art Research facility of 100,000 sq. ft +, accommodating end-to-end capabilities for product delivery across entire product R&D lifecycle. We are a leading Research company backed by a strong team of 300+ competent scientists focussed on making us a one-stop shop to ensure seamless delivery of highly complex products. Our focus is on developing generic pharmaceutical product and 505(b)(2) products with complex chemistry, technological barriers, and limited competition for the global markets. We have extensive experience in developing cutting edge solutions, proprietary processes and technologies to deliver products across multiple delivery platforms, including nano-suspensions, nano-emulsions, liposomes, nanoparticles, and long-acting polymeric injectable suspensions. Our pipeline includes Complex Injectables, Topicals, Ophthalmics, Parenterals, Nasal Sprays /Inhalations and Complex Peptide combination products that target various treatment indications. Our pipeline is characteristic of product domain that is complex, has entry barriers and a is lucrative. We are an outcome driven and value generating organization creating growth partnerships for global pharma players across the entire spectrum of Complex Generics. Our vision is aptly captured in our tag line: Performance Excellence Delivered ! To know more about Orbicular Pharmaceutical Technologies, visit https://orbicular.co.in or reach out to us at hr.dept@orbicular.co.in!

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing. We today rank among the top 50 pharmaceutical companies in India and enjoy a multi-therapeutic presence across segments like anti-infectives, Our pharmaceutical solutions include active pharmaceutical ingredients (API), We are globally present across 40+ countries through alliances and partnerships with globally reputed majors. Our integrated business model enables us to cater to business opportunities throughout the value chain, from research to delivery of drugs across therapeutic segments. Our niche product basket helps us maintain an edge over our peers in the markets where we are present. In the years to come, driven by a highly competent and motivated team, we will move from strength to strength in the key domains of API, and global generics. On March 31, 2020, the resolution plan under CIRP has been implemented and the Board has been re-constituted with the members nominated by Dhanuka Laboratories Limited,

Oxford Pharmaceuticals is a pharmaceutical manufacturer specializing in generic oral solid tablets, operating a state-of-the-art facility with a focus on quality control and regulatory compliance.

Panacea Biotec is a research-based health management company involved in research, manufacturing and marketing of high-quality, affordable pharmaceutical, vaccines and herbal products. The product portfolio includes highly innovative prescription products in important therapeutic areas like pain management, diabetes, cardiovascular, renal disease management, osteoporosis, gastro-intestinal care products and vaccines. Panacea Biotec is committed towards disease prevention by introducing Innovative Vaccines that helps to reduce child mortality. Our portfolio consists of worlds first fully liquid Hexavalent vaccine i.e. EasySix (DTwP-Hib-HepB-IPV), the world’s first fully-liquid Pentavalent vaccine i.e. Easyfive-TT (DTwP-Hib-HepB), Oral Polio vaccines (like bOPV, tOPV, mOPV), etc. We have a high-impact pipeline of vaccines including Pneumococcal conjugate vaccines (PCV), tetravalent dengue vaccine, etc. We have supplied 10+ billion immunizations of Polio vaccines in last 20 years, 150+ million immunizations of Novel Innovative fully liquid wP-based vaccines like the wP-Hexavalent vaccine (DTwP-Hib-HepB-IPV). And are a trusted partner for WHO, GAVI and UN Agencies with track-record of sustainable supplies for UNICEF, PAHO, and National Immunization Programs. In Pharmaceuticals, we have discovered and commercialised a NCE, Sitcom – that helps in Haemorrhoids and Piles. It is the leading brand in its segment in India and many other countries. We also have built leading brands like Pangraf, Mycept, Glizid, Livoluk, and PacliAll across transplantation, diabetes, constipation, and oncology. Our facilities are WHO Prequalified, US FDA approved and cGMP compliant. Our products are available across more than 145 countries including US, Germany, among other markets.

At PlatinumRx, we are revolutionizing the pharma industry with transparency and affordability. Empowering you with the best medicine choices at unbeatable prices. Breaking barriers in healthcare, we're not just another e-pharmacy; we're a movement towards informed, cost-effective health solutions. Join our journey!

SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families. Who are we? - We believe in delivering solutions that matter to the people of today and innovating for the people of tomorrow. - To us, it is more than a business - it is a mission. What do we do? - We combine a specialty pharmaceutical business with a leading biologics biotechnology engine. - We partner to bring the best drugs we can find to the patients who need it most. How do we do it? - Our efforts aim to deliver better patient outcomes through better science. - We understand that humility and service matter as it is not about us, it is about making patients’ lives better.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is a prominent global pharmaceutical company based in India. Established in 1983, it has grown to become the largest pharmaceutical company in India and the fifth-largest specialty generic pharmaceutical company worldwide. Sun Pharma specializes in generic and specialty pharmaceuticals, focusing on chronic therapies in areas such as cardiology, psychiatry, neurology, gastroenterology, and oncology. The company operates in over 100 countries, with significant markets in the U.S., India, and emerging economies. Sun Pharma produces a diverse range of off-patent generic drugs, including tablets, capsules, injectables, and topical formulations. It also develops complex generics and specialty products for various conditions. The company has a strong commitment to research and development, investing in novel drug delivery systems and biosimilars. With 43 manufacturing facilities across five continents and a workforce of over 37,000, Sun Pharma continues to expand its global footprint and enhance its product offerings.

THINQ is a totally vertically integrated service and product provider for pharmaceutical companies offering the below services: - Contract R&D Contract Manufacturing - API Development, Manufacturing and Marketing - Formulation Development & Marketing

Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It has 3 research centers and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Headquartered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health. Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.